Meeting
2019 ASCO Annual Meeting
Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.
Authors
Yucai Wang
Mayo Clinic, Rochester, MN
Yucai Wang , Shouhao Zhou , Fang Yang , Grzegorz S. Nowakowski , Thomas Matthew Habermann , Michael Wang , Thomas E. Witzig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7556)
DOI
10.1200/JCO.2019.37.15_suppl.7556
Abstract #
7556
Poster Bd #
310
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.
First Author: William Townsend
Poster
2023 ASCO Annual Meeting
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
First Author: Loretta J. Nastoupil
Poster
2023 ASCO Annual Meeting
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
First Author: Laurie Helen Sehn
Poster
2023 ASCO Annual Meeting
A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
First Author: Adam J Olszewski